These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future. Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443 [TBL] [Abstract][Full Text] [Related]
25. Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. Kurian AW; Kingham KE; Ford JM Curr Opin Obstet Gynecol; 2015 Feb; 27(1):23-33. PubMed ID: 25502425 [TBL] [Abstract][Full Text] [Related]
26. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876 [TBL] [Abstract][Full Text] [Related]
27. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
28. [Risk-reducing surgery in women at hereditary risk of gynaecological cancer]. Zikán M Ceska Gynekol; 2011 Jun; 76(3):216-21. PubMed ID: 21838153 [TBL] [Abstract][Full Text] [Related]
33. Hereditary breast-ovarian cancer: clinical findings and medical management. Marshall M; Solomon S Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820 [TBL] [Abstract][Full Text] [Related]
34. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations. Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124 [TBL] [Abstract][Full Text] [Related]
35. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453 [TBL] [Abstract][Full Text] [Related]
39. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Tinelli A; Malvasi A; Leo G; Vergara D; Pisanò M; Ciccarese M; Chiuri VE; Lorusso V Cancer Metastasis Rev; 2010 Jun; 29(2):339-50. PubMed ID: 20405170 [TBL] [Abstract][Full Text] [Related]
40. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]